Cargando…

Cholesterol Embolization Syndrome After Kidney Transplantation: A Case Series and Systematic Review

BACKGROUND. Cholesterol embolization syndrome (CES) is an uncommon but well-known cause of renal failure in native kidneys, but little is known about CES in kidney transplant recipients. The aim of this study was to determine the incidence, clinical characteristics, histopathology, and prognosis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Francke, Marith I., Clahsen-van Groningen, Marian C., van den Bosch, Thierry P. P., Becker, Jan U., Hesselink, Dennis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384396/
https://www.ncbi.nlm.nih.gov/pubmed/34476296
http://dx.doi.org/10.1097/TXD.0000000000001158
_version_ 1783741906804539392
author Francke, Marith I.
Clahsen-van Groningen, Marian C.
van den Bosch, Thierry P. P.
Becker, Jan U.
Hesselink, Dennis A.
author_facet Francke, Marith I.
Clahsen-van Groningen, Marian C.
van den Bosch, Thierry P. P.
Becker, Jan U.
Hesselink, Dennis A.
author_sort Francke, Marith I.
collection PubMed
description BACKGROUND. Cholesterol embolization syndrome (CES) is an uncommon but well-known cause of renal failure in native kidneys, but little is known about CES in kidney transplant recipients. The aim of this study was to determine the incidence, clinical characteristics, histopathology, and prognosis of CES after kidney transplantation. METHODS. CES cases in both transplanted and native kidneys (control group) were identified by searching the databases of the divisions of Nephrology and Pathology of our institution. Clinical data were retrospectively collected. Biopsies were classified according to the latest Banff 2019 Update. Second, a systematic literature search was performed (December 01, 2020) of Ovid MEDLINE, EMBASE, the Cochrane Central Register of controlled trials, Google Scholar, and Web of Science. RESULTS. CES was observed in for-cause biopsies of 11 out of 2350 (0.47%) kidney transplant recipients transplanted between January 1, 2006, and December 31, 2018 (0.0009 cases per person-year). All patients had ≥1 cardiovascular risk factor, and 9 donors were expanded criteria donors. Graft loss occurred in 27.3% of the patients diagnosed with CES. Eight transplant biopsies with CES were also classified as biopsy-proven acute rejection. Transplant biopsies showed signs of inflammation (arteritis, n = 7; interstitial inflammation, n = 5; tubulitis, n = 7). One patient with CES in a native kidney was identified. The biopsy of the native kidney only showed arteritis and classified as an isolated “v” lesion. The literature search resulted in 188 unique articles of which 20 were included. A total of 47 cases of CES after kidney transplantation was reported. Cholesterol emboli were found in <1% of all kidney transplant biopsies. In 57.8% of the kidney transplant biopsies with CES described in literature, concomitant inflammation was present. CONCLUSIONS. CES is an uncommon cause of kidney transplant failure, although the incidence of CES may be underestimated. CES may mimic rejection as it can be accompanied by arteritis.
format Online
Article
Text
id pubmed-8384396
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-83843962021-09-01 Cholesterol Embolization Syndrome After Kidney Transplantation: A Case Series and Systematic Review Francke, Marith I. Clahsen-van Groningen, Marian C. van den Bosch, Thierry P. P. Becker, Jan U. Hesselink, Dennis A. Transplant Direct Kidney Transplantation BACKGROUND. Cholesterol embolization syndrome (CES) is an uncommon but well-known cause of renal failure in native kidneys, but little is known about CES in kidney transplant recipients. The aim of this study was to determine the incidence, clinical characteristics, histopathology, and prognosis of CES after kidney transplantation. METHODS. CES cases in both transplanted and native kidneys (control group) were identified by searching the databases of the divisions of Nephrology and Pathology of our institution. Clinical data were retrospectively collected. Biopsies were classified according to the latest Banff 2019 Update. Second, a systematic literature search was performed (December 01, 2020) of Ovid MEDLINE, EMBASE, the Cochrane Central Register of controlled trials, Google Scholar, and Web of Science. RESULTS. CES was observed in for-cause biopsies of 11 out of 2350 (0.47%) kidney transplant recipients transplanted between January 1, 2006, and December 31, 2018 (0.0009 cases per person-year). All patients had ≥1 cardiovascular risk factor, and 9 donors were expanded criteria donors. Graft loss occurred in 27.3% of the patients diagnosed with CES. Eight transplant biopsies with CES were also classified as biopsy-proven acute rejection. Transplant biopsies showed signs of inflammation (arteritis, n = 7; interstitial inflammation, n = 5; tubulitis, n = 7). One patient with CES in a native kidney was identified. The biopsy of the native kidney only showed arteritis and classified as an isolated “v” lesion. The literature search resulted in 188 unique articles of which 20 were included. A total of 47 cases of CES after kidney transplantation was reported. Cholesterol emboli were found in <1% of all kidney transplant biopsies. In 57.8% of the kidney transplant biopsies with CES described in literature, concomitant inflammation was present. CONCLUSIONS. CES is an uncommon cause of kidney transplant failure, although the incidence of CES may be underestimated. CES may mimic rejection as it can be accompanied by arteritis. Lippincott Williams & Wilkins 2021-06-18 /pmc/articles/PMC8384396/ /pubmed/34476296 http://dx.doi.org/10.1097/TXD.0000000000001158 Text en Copyright © 2021 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Kidney Transplantation
Francke, Marith I.
Clahsen-van Groningen, Marian C.
van den Bosch, Thierry P. P.
Becker, Jan U.
Hesselink, Dennis A.
Cholesterol Embolization Syndrome After Kidney Transplantation: A Case Series and Systematic Review
title Cholesterol Embolization Syndrome After Kidney Transplantation: A Case Series and Systematic Review
title_full Cholesterol Embolization Syndrome After Kidney Transplantation: A Case Series and Systematic Review
title_fullStr Cholesterol Embolization Syndrome After Kidney Transplantation: A Case Series and Systematic Review
title_full_unstemmed Cholesterol Embolization Syndrome After Kidney Transplantation: A Case Series and Systematic Review
title_short Cholesterol Embolization Syndrome After Kidney Transplantation: A Case Series and Systematic Review
title_sort cholesterol embolization syndrome after kidney transplantation: a case series and systematic review
topic Kidney Transplantation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384396/
https://www.ncbi.nlm.nih.gov/pubmed/34476296
http://dx.doi.org/10.1097/TXD.0000000000001158
work_keys_str_mv AT franckemarithi cholesterolembolizationsyndromeafterkidneytransplantationacaseseriesandsystematicreview
AT clahsenvangroningenmarianc cholesterolembolizationsyndromeafterkidneytransplantationacaseseriesandsystematicreview
AT vandenboschthierrypp cholesterolembolizationsyndromeafterkidneytransplantationacaseseriesandsystematicreview
AT beckerjanu cholesterolembolizationsyndromeafterkidneytransplantationacaseseriesandsystematicreview
AT hesselinkdennisa cholesterolembolizationsyndromeafterkidneytransplantationacaseseriesandsystematicreview